{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T22:10:04Z","timestamp":1762035004087,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004166","name":"Warszawski Uniwersytet Medyczny","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.advms.2020.12.007","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T19:20:09Z","timestamp":1611343209000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metabolic mediators determine the association of antinuclear antibody subtypes with specific clinical symptoms in systemic sclerosis"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4447-282X","authenticated-orcid":false,"given":"Anna","family":"Stochmal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-7281","authenticated-orcid":false,"given":"Joanna","family":"Czuwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-4278","authenticated-orcid":false,"given":"Micha\u0142","family":"Zaremba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-1023","authenticated-orcid":false,"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2020.12.007_bib1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.advms.2020.12.007_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12026-017-8926-y","article-title":"Pathogenesis of systemic sclerosis-current concept and emerging treatments","volume":"65","author":"Furue","year":"2017","journal-title":"Immunol Res"},{"issue":"9","key":"10.1016\/j.advms.2020.12.007_bib3","first-page":"789","article-title":"Meta-analysis of circulating adiponectin, leptin, and resistin levels in systemic sclerosis","volume":"76","author":"Lee","year":"2017","journal-title":"Z\u00a0Rheumatol"},{"key":"10.1016\/j.advms.2020.12.007_bib4","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3389\/fimmu.2018.02045","article-title":"Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door Be closed?","volume":"9","author":"Bruni","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.84.56","article-title":"Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting","volume":"84","author":"Kuwana","year":"2017","journal-title":"J\u00a0Nippon Med Sch"},{"key":"10.1016\/j.advms.2020.12.007_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-6-2","article-title":"Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis","volume":"6","author":"Parker","year":"2009","journal-title":"J\u00a0Autoimmune Dis"},{"key":"10.1016\/j.advms.2020.12.007_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.03.030","article-title":"Adipokines: linking metabolic syndrome, the immune system, and arthritic diseases","author":"Francisco","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.advms.2020.12.007_bib9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00296-019-04371-z","article-title":"Comorbidity burden in systemic sclerosis: beyond disease-specific complications","volume":"39","author":"Pagkopoulou","year":"2019","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.advms.2020.12.007_bib10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00403-019-01993-y","article-title":"Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis","volume":"312","author":"Stochmal","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cmet.2013.01.001","article-title":"Adiponectin receptor as a key player in healthy longevity and obesity-related diseases","volume":"17","author":"Yamauchi","year":"2013","journal-title":"Cell Metabol"},{"issue":"10","key":"10.1016\/j.advms.2020.12.007_bib12","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.biochi.2012.05.018","article-title":"Immunological functions of leptin and adiponectin","volume":"94","author":"Carbone","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.advms.2020.12.007_bib13","doi-asserted-by":"crossref","first-page":"658913","DOI":"10.1155\/2014\/658913","article-title":"New insight into adiponectin role in obesity and obesity-related diseases","volume":"2014","author":"Nigro","year":"2014","journal-title":"BioMed Res Int"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib14","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1038\/s41598-017-04162-1","article-title":"Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target","volume":"7","author":"Marangoni","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/14397595.2016.1193106","article-title":"Serum adipokines levels in patients with systemic sclerosis: a meta-analysis","volume":"27","author":"Zhao","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.metabol.2014.10.014","article-title":"Leptin in autoimmune diseases","volume":"64","author":"Procaccini","year":"2015","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mce.2009.08.018","article-title":"Adipose tissue as an endocrine organ","volume":"316","author":"Galic","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.advms.2020.12.007_bib18","doi-asserted-by":"crossref","first-page":"568343","DOI":"10.1155\/2010\/568343","article-title":"Role of leptin in the activation of immune cells","volume":"2010","author":"Fernandez-Riejos","year":"2010","journal-title":"Mediat Inflamm"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib19","first-page":"68","article-title":"Role of leptin in autoimmune diseases","volume":"8","author":"Cojocaru","year":"2013","journal-title":"Maedica (Buchar)."},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2007.01.011","article-title":"A\u00a0key role of leptin in the control of regulatory T cell proliferation","volume":"26","author":"De Rosa","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.advms.2020.12.007_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2018.03.011","article-title":"Leptin in autoimmune mechanisms of systemic rheumatic diseases","volume":"423","author":"Navarini","year":"2018","journal-title":"Canc Lett"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib22","first-page":"148","article-title":"Chemerin, resistin, and adiponectin in patients with connective tissue diseases","volume":"37","author":"Grygiel-Gorniak","year":"2018","journal-title":"J\u00a0Med Biochem"},{"issue":"6","key":"10.1016\/j.advms.2020.12.007_bib23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11926-013-0336-0","article-title":"The role of resistin in inflammatory myopathies","volume":"15","author":"Filkova","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.advms.2020.12.007_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cyto.2018.11.013","article-title":"Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement","volume":"117","author":"Neumann","year":"2019","journal-title":"Cytokine"},{"issue":"2\u20133","key":"10.1016\/j.advms.2020.12.007_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12026-011-8222-1","article-title":"CD8+ T cells in systemic sclerosis","volume":"50","author":"Fuschiotti","year":"2011","journal-title":"Immunol Res"},{"issue":"8","key":"10.1016\/j.advms.2020.12.007_bib26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00296-013-2880-3","article-title":"Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis","volume":"34","author":"Masui","year":"2014","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13075-017-1472-0","article-title":"Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis","volume":"19","author":"Sato","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.advms.2020.12.007_bib28","first-page":"144","article-title":"Resistin: a possible biomarker of organ involvement in systemic sclerosis patients?","volume":"35","author":"Sawicka","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/diseases6020038","article-title":"Pulmonary arterial hypertension: pathophysiology and treatment","volume":"6","author":"Lan","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.advms.2020.12.007_bib30","article-title":"Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis","author":"Elisa","year":"2015","journal-title":"J\u00a0Immunol Res"},{"issue":"8","key":"10.1016\/j.advms.2020.12.007_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/exd.13264","article-title":"Endothelial cell-derived endothelin-1 is involved in abnormal scar formation by dermal fibroblasts through RhoA\/Rho-kinase pathway","volume":"26","author":"Kiya","year":"2017","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.advms.2020.12.007_bib32","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.phrs.2011.01.011","article-title":"The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis","volume":"63","author":"Leask","year":"2011","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-017-1271-7","article-title":"Increased serum levels of fractalkine and mobilisation of CD34(+)CD45(-) endothelial progenitor cells in systemic sclerosis","volume":"19","author":"Benyamine","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.advms.2020.12.007_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00005-016-0395-9","article-title":"Role of CX3CL1 in diseases","volume":"64","author":"Liu","year":"2016","journal-title":"Arch Immunol Ther Exp"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib35","doi-asserted-by":"crossref","first-page":"16833","DOI":"10.1038\/s41598-017-17007-8","article-title":"Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration","volume":"7","author":"Ishida","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.advms.2020.12.007_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cytogfr.2017.12.001","article-title":"Fractalkine and placental growth factor: a duet of inflammation and angiogenesis in cardiovascular disorders","volume":"39","author":"Skoda","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.advms.2020.12.007_bib37","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.3892\/etm.2017.4862","article-title":"Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus","volume":"14","author":"Guo","year":"2017","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/ard.2003.018705","article-title":"Up regulated expression of fractalkine\/CX3CL1 and CX3CR1 in patients with systemic sclerosis","volume":"64","author":"Hasegawa","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/JLB.3A0317-110R","article-title":"Galectin-3 type-C self-association on neutrophil surfaces; the carbohydrate recognition domain regulates cell function","volume":"103","author":"Sundqvist","year":"2018","journal-title":"J\u00a0Leukoc Biol"},{"issue":"1\u20132","key":"10.1016\/j.advms.2020.12.007_bib40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12026-012-8286-6","article-title":"The roles of Galectin-3 in autoimmunity and tumor progression","volume":"52","author":"Radosavljevic","year":"2012","journal-title":"Immunol Res"},{"issue":"5","key":"10.1016\/j.advms.2020.12.007_bib41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.autrev.2008.11.009","article-title":"The immunological potential of galectin-1 and -3","volume":"8","author":"Dhirapong","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib42","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.114.218370","article-title":"Functions of galectin-3 and its role in fibrotic diseases","volume":"351","author":"Li","year":"2014","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"10","key":"10.1016\/j.advms.2020.12.007_bib43","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/glycob\/cwu086","article-title":"Galectin-3 in angiogenesis and metastasis","volume":"24","author":"Funasaka","year":"2014","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.advms.2020.12.007_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10067-013-2346-8","article-title":"Serum galectin-3 level in systemic sclerosis","volume":"33","author":"Koca","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.advms.2020.12.007_bib45","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.advms.2020.12.007_bib46","first-page":"483","article-title":"Systemic sclerosis \u2013 diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1: diagnosis and monitoring","volume":"104","author":"Krasowska","year":"2017","journal-title":"Dermatology Review\/Przegl\u0105d Dermatologiczny"},{"issue":"4","key":"10.1016\/j.advms.2020.12.007_bib47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00403-019-01893-1","article-title":"The role of adipokines in systemic sclerosis: a missing link?","volume":"311","author":"Zolkiewicz","year":"2019","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"10.1016\/j.advms.2020.12.007_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206545","article-title":"Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis","volume":"13","author":"Hoffmann-Vold","year":"2018","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.advms.2020.12.007_bib49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00403-018-1821-0","article-title":"Leptin regulates the pro-inflammatory response in human epidermal keratinocytes","volume":"310","author":"Lee","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"10.1016\/j.advms.2020.12.007_bib50","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00296-013-2668-5","article-title":"Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients","volume":"33","author":"Poormoghim","year":"2013","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.advms.2020.12.007_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.advms.2020.12.007_bib52","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.semarthrit.2017.10.006","article-title":"ACR\/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension","volume":"47","author":"Joven","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.advms.2020.12.007_bib53","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.advms.2020.12.007_bib54","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.advms.2020.12.007_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2016.12.140","article-title":"Galectin-3 is an independent predictor of survival in systemic sclerosis","volume":"233","author":"Faludi","year":"2017","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.advms.2020.12.007_bib56","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.38428","article-title":"Clinical and serologic correlates of anti-PM\/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients","volume":"66","author":"D\u2019Aoust","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.advms.2020.12.007_bib57","article-title":"The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients","author":"Rodsaward","year":"2019","journal-title":"Asian Pac J Allergy Immunol"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112620300511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112620300511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:43:14Z","timestamp":1761824594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112620300511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1896112620300511"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2020.12.007","relation":{},"ISSN":["1896-1126"],"issn-type":[{"type":"print","value":"1896-1126"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic mediators determine the association of antinuclear antibody subtypes with specific clinical symptoms in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}